Global epidemiology of amyloid light-chain amyloidosis
Tóm tắt
Amyloid light-chain (AL) amyloidosis is an ultra-rare disease associated with significant morbidity and mortality. Few studies have examined the global epidemiology of this condition. This study estimated the diagnosed incidence and 1-year, 5-year, 10-year, and 20-year period prevalence of AL amyloidosis in 2018 for countries in and near Europe, and in the United States (US), Canada, Brazil, Japan, South Korea, Taiwan, and Russia. A systematic literature review (SLR) was conducted to identify country-specific, age- and gender-specific diagnosed incidence of AL amyloidosis and observed survival data-point inputs for an incidence-to-prevalence model. Extrapolations were used to estimate incidence and prevalence for countries without registry or published epidemiological data. Of 171 publications identified in the SLR, 10 records met the criteria for data extraction, and two records were included in the final incidence-to-prevalence model. In 2018, an estimated 74,000 AL amyloidosis cases worldwide were diagnosed during the preceding 20 years. The estimated incidence and 20-year prevalence rates were 10 and 51 cases per million population, respectively. Orphan medicinal product designation criteria of the European Medicines Agency or Electronic Code of Federal Regulations indicate that a disease must not affect > 5 in 10,000 people across the European Union or affect < 200,000 people in the US. This study provides up-to-date epidemiological patterns of AL amyloidosis, which is vital for understanding the burden of the disease, increasing awareness, and to further research and treatment options.
Tài liệu tham khảo
Hazenberg BPC. Amyloidosis: a clinical overview. Rheum Dis Clin North Am. 2013;39(2):323–45. https://doi.org/10.1016/j.rdc.2013.02.012.
Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111–9. https://doi.org/10.1182/blood-2016-11-751628.
Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2(10):1046–53. https://doi.org/10.1182/bloodadvances.2018016402.
Al Hamed R, Bazarbachi AH, Bazarbachi A, et al. Comprehensive review of AL amyloidosis: some practical recommendations. Blood Cancer J. 2021;11(5):97. https://doi.org/10.1038/s41408-021-00486-4.
Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther. 2015;32(10):920–8. https://doi.org/10.1007/s12325-015-0250-0.
Sidiqi MH, Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. Blood Cancer J. 2021;11(5):90. https://doi.org/10.1038/s41408-021-00483-7.
Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–7. https://doi.org/10.1200/JCO.2004.03.029.
Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–5. https://doi.org/10.1182/blood-2015-01-620302.
Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–7. https://doi.org/10.1182/blood-2012-12-473066.
Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95. https://doi.org/10.1200/JCO.2011.38.5724.
Lilleness B, Ruberg FL, Mussinelli R, et al. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood. 2019;133(3):215–23. https://doi.org/10.1182/blood-2018-06-858951.
Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38. https://doi.org/10.1038/s41572-018-0034-3.
Palladini G, Miolani MG. Management of AL amyloidosis in 2020. Blood. 2020;136(23):2620–7.
Kastritis E, Dispenzieri A, Wechalekar AD, et al. Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial. J Clin Oncol. 2020;38(Suppl 15):8546. https://doi.org/10.1200/JCO.2020.38.15_suppl.8546.
Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):71–80. https://doi.org/10.1182/blood.2019004460.
Food and Drug Administration. FDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-darzalex-faspro-newly-diagnosed-light-chain-amyloidosis. Accessed 15 October 2021.
Dispenzieri A, Kastritis E, Wechalekar AD, et al. A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis. Leukemia. 2022;36(1):225–35. https://doi.org/10.1038/s41375-021-01317-y.
Kastritis E, Sanchorawala V, Merlini G, et al. Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. J Clin Oncol. 2021;39(Suppl 15):8003. https://doi.org/10.1200/JCO.2021.39.15_suppl.8003.
Quock TP, Yan T, Chang E, et al. Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data. J Comp Eff Res. 2018;7(6):549–59. https://doi.org/10.2217/cer-2017-0100.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. https://doi.org/10.1136/bmj.b2700.
Aguirre MA, Boietti BR, Nucifora E, et al. Incidence rate of amyloidosis in patients from a medical care program in Buenos Aires, Argentina: a prospective cohort. Amyloid. 2016;23(3):184–7. https://doi.org/10.1080/13506129.2016.1207626.
Duhamel S, Mohty D, Magne J, et al. Incidence and prevalence of light chain amyloidosis: a population-based study. Blood. 2017;130(Suppl 1):5577. https://doi.org/10.1182/blood.V130.Suppl_1.5577.5577.
Hemminki K, Li X, Försti A, et al. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health. 2012;12:974. https://doi.org/10.1186/1471-2458-12-974.
Huang X, Wang Q, Jiang S, et al. The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients. Clin Kidney J. 2015;8(1):120–6. https://doi.org/10.1093/ckj/sfu117.
Kourelis TV, Kyle RA, Dingli D, et al. Presentation and outcomes of localized immunoglobulin light chain amyloidosis: the Mayo clinic experience. Mayo Clin Proc. 2017;92(6):908–17. https://doi.org/10.1016/j.mayocp.2017.02.016.
Magy-Bertrand N, Dupond JL, Mauny F, et al. Incidence of amyloidosis over 3 years: the AMYPRO study. Clin Exp Rheumatol. 2008;26(6):1074–8.
Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161(4):525–32. https://doi.org/10.1111/bjh.12286.
Seo SR, Jang SY, Lee GY, et al. Prevalence of amyloidosis in Korea. Orphanet J Rare Dis. 2017;12(1):152. https://doi.org/10.1186/s13023-017-0705-2.
Weiss BM, Lund SH, Bjorkholm M, et al. Improved survival in AL amyloidosis: a population-based study on 1,430 patients diagnosed in Sweden 1995–2013. Blood. 2016;128(22):4448. https://doi.org/10.1182/blood.V128.22.4448.4448.
Lin HM, Gao X, Cooke CE, et al. Disease burden of systemic light-chain amyloidosis: a systematic literature review. Curr Med Res Opin. 2017;33(6):1017–31. https://doi.org/10.1080/03007995.2017.1297930.
United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects. 2017. https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Jan/un_2017_world_population_prospects-2017_revision_databooklet.pdf. Accessed 26 January 2022.
European Medicines Agency. Points to consider on the estimation and reporting on the prevalence of a condition for the purpose of orphan designation. 2019. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/points-consider-estimation-reporting-prevalence-condition-orphan-designation_en.pdf. Accessed 15 June 2021.
Electronic Code of Federal Regulations. Part 316 - Orphan Drugs. Section 316.20 Content and format of a request for orphan-drug designation. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-316. Accessed 15 June 2021.
US Census Bureau. U.S. and world population clock. https://www.census.gov/popclock. Accessed 3 December 2021.
Barrett CD, Dobos K, Liedtke M, et al. A changing landscape of mortality for systemic light chain amyloidosis. JACC Heart Fail. 2019;7(11):958–66. https://doi.org/10.1016/j.jchf.2019.07.007.
Vaxman I, Gertz M. When to suspect a diagnosis of amyloidosis. Acta Haematol. 2020;143(4):304–11. https://doi.org/10.1159/000506617.